$13.40
0.45% yesterday
Nasdaq, Nov 25, 09:45 pm CET
ISIN
US05463X1063
Symbol
AXGN

AxoGen, Inc. Stock price

$13.47
+0.16 1.20% 1M
+7.20 114.83% 6M
+6.64 97.22% YTD
+7.49 125.25% 1Y
+3.04 29.15% 3Y
-3.52 20.72% 5Y
+10.54 359.73% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.13 0.97%
ISIN
US05463X1063
Symbol
AXGN
Sector

Key metrics

Market capitalization $592.79m
Enterprise Value $631.12m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.49
P/S ratio (TTM) P/S ratio 3.28
P/B ratio (TTM) P/B ratio 5.96
Revenue growth (TTM) Revenue growth 18.79%
Revenue (TTM) Revenue $180.86m
EBIT (operating result TTM) EBIT $-8.50m
Free Cash Flow (TTM) Free Cash Flow $-8.31m
Cash position $30.53m
EPS (TTM) EPS $-0.33
P/E forward negative
P/S forward 3.20
EV/Sales forward 3.40
Short interest 3.05%
Show more

Is AxoGen, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

AxoGen, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a AxoGen, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a AxoGen, Inc. forecast:

Buy
100%

Financial data from AxoGen, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
181 181
19% 19%
100%
- Direct Costs 43 43
52% 52%
24%
138 138
11% 11%
76%
- Selling and Administrative Expenses 111 111
4% 4%
61%
- Research and Development Expense 28 28
2% 2%
16%
-0.72 -0.72
96% 96%
0%
- Depreciation and Amortization 7.78 7.78
60% 60%
4%
EBIT (Operating Income) EBIT -8.50 -8.50
64% 64%
-5%
Net Profit -14 -14
38% 38%
-8%

In millions USD.

Don't miss a Thing! We will send you all news about AxoGen, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AxoGen, Inc. Stock News

Neutral
Seeking Alpha
17 days ago
Axogen, Inc (NASDAQ:AXGN ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - ...
Neutral
GlobeNewsWire
3 months ago
ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®.
Neutral
Seeking Alpha
4 months ago
AxoGen, Inc. (NASDAQ:AXGN ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Harold Tamayo - Vice President-Finance and Investor Relations Karen Zaderej - Chairman, Chief Executive Officer and President Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Catlin Cronin - Canaccord Genuity Jay...
More AxoGen, Inc. News

Company Profile

AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Head office United States
CEO Michael Dale
Employees 428
Founded 1977
Website www.axogeninc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today